List of works - Gerald Falchook

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

scientific article published oln 16 November 2016

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

scientific article

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial ⬇️

scientific article published on July 16, 2012

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

scientific article

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

scientific article

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

scientific article

BRAF mutations in advanced cancers: clinical characteristics and outcomes

scientific article (publication date: 2011)

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience

scientific article

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

scientific article

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

scientific article

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

scientific article

Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations

scientific article

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

scientific article

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer

scientific article

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

scientific article

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

scientific article

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients

scientific article

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study

scientific article

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

scientific article

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

scientific article

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit

scientific article

Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib ⬇️

scientific article published on March 1, 2013

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

scientific article

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

scientific article

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

scientific article

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

scientific article

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors ⬇️

scientific article published on April 23, 2012

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer

scientific article

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

scientific article

Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer

scientific article

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

scientific article

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer

scientific article

Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience

scientific article

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy

scientific article

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

scientific article

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

scientific article

Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors

scientific article published on 19 July 2013

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

scientific article

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer

scientific article

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

scientific article

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial ⬇️

scientific article published on July 16, 2012

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience

scientific article

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations

scientific article

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

scientific article

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

scientific article published on 05 July 2013

Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial

scientific article

List of works by Gerald Falchook

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial ⬇️

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

BRAF mutations in advanced cancers: clinical characteristics and outcomes

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit

Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib ⬇️

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors ⬇️

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer

Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial ⬇️

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).

Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial